XENOGEN ANNOUNCES EXTENSION OF GLOBAL LICENSING AGREEMENT

Xenogen Corporation announced today an extension of its licensing agreement with Novartis for up to two more years. Novartis will continue to license Xenogen's proprietary software (Living Image(R) Software) and patented methods of biophotonic imaging for use with Xenogen's biophotonic imaging systems (IVIS(R) Imaging Systems). The technology will be used for research in several therapeutic areas at Novartis research sites in the United States, Japan and Switzerland. This is an extension of the original agreement between the two companies that was signed in 2000.

Finanzen (http://finanzen.net/news/news_detail.asp?NewsNr=356472)